Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...
On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...
The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...
The People vs. AbbVie
Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...
Are gene-editing therapies patentable? A WIPO side event investigates.
On 6 December, Knowledge Ecology International (KEI) organised an interesting panel on the patentability of new gene- and cell-based medical therapies, as a side...
Chile’s Technology and Knowledge Transfer Bill passes Congress with important commitments on socially responsible...
On 9 June, the Chilean Congress approved a Technology and Knowledge Transfer bill (Ley de Transferencia de TecnologÃa y Conocimiento) that makes important strides...
World Health Organization Members ask for more time to solve difficult negotiations on access...
World Health Organization member states will propose to continue negotiations on a critical annex to the Pandemic Agreement, after being unable to bridge key...
WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument
In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...
WIPO and pharma industry launch global medicines patent database
On 25 September, the World Intellectual Property Organisation (WIPO) in collaboration with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launched the Patent...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda
On Thursday 24 January, the World Health Organization’s 144th Executive Board meeting will kick off in Geneva. One of the agenda items is access...